PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its plans to ...
Following intravenous administration, ADCs circulate in the bloodstream (①) and specifically bind to their target antigen on the tumor cell surface (②). The antigen–ADC complex undergoes ...
Building on proven targeting of the F H AB domain, Sonnet’s ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback